Neurorehabilitation News

Autism spectrum disorder incidence was higher for children with prenatal exposure to antiseizure medications vs. the general population, but some associations weakened after adjusting for treatment indication, researchers reported.

Antidopaminergic medications were linked to worsening cognitive and functional effects that accelerate disease progression in Huntington’s disease, according to research presented at the Congress of the European Academy of Neurology.

The FDA has granted Regenerative Medicine Advanced Therapy designation to a Bay Area-based biopharmaceutical company for its autologous, fully human CD19 chimeric antigen receptor to treat those with refractory stiff person syndrome.

NYU Langone was again the top hospital in the United States for neurology and neurosurgery, according to the latest annual Best Hospitals Survey issued by U.S. News & World Report.

A Brooklyn-based biotech firm has announced successful completion of the first phase of a preclinical study conducted with the Walter Reed Army Institute of Research involving a proprietary hemostatic hydrogel to treat traumatic brain injury.

Individuals with moderate to less severe treatment-resistant depression may benefit from treatment with ketamine instead of electroconvulsive therapy, according to research from JAMA Network Open.

No significant differences were found in clinical outcomes or recovery time in college athletes who returned to play following concussion compared with those immediately removed, according to research from Neurosurgical Focus.

Interim results of phase 1/2 clinical trials of an investigational gene therapy for Huntington’s disease showed that disease progression slowed by 80% at 24 months, according to the manufacturer.

Significant dose-response associations were found for transcranial magnetic stimulation and transcranial direct current stimulation across several mental disorders, including schizophrenia and depression, according to research.

A South Korean biomedical company has announced positive 1-year assessment data from a phase 1/2a clinical trial of a human embryonic stem cell-derived midbrain dopaminergic progenitor for Parkinson’s disease.